Financials

  • Market Capitalization 20.26 M
  • Employee 6
  • Founded 2009
  • CEO N/A
  • Website www.kalarx.com
  • Headquarter Delaware, United States
  • FIGI BBG001J2MVT8
  • Industry Biotecnologia
Ricavi totali
Utile netto
Utile base per azione (EPS base)
Debito totale
Liquidità libera
Disponibilità liquide e mezzi equivalenti
Rapporto prezzo/utili
-0.17
Rapporto prezzo/fatturato

Related tickers

#NomePrezzo24h %7d %1M %1Y %Valore di MercatoUltimi 7 Giorni
4606
TVGN
Tevogen Bio Holdings Inc. - Common Stock
5.00 USD-1.19%-15.40%-52.02%+296.83%20.94 M USD
4611
ATOS
Atossa Therapeutics, Inc. - Common Stock
2.40 USD+1.27%+1.27%-4.38%+155.32%20.67 M USD
4629
LGVN
Longeveron Inc. - Class A Common stock
0.63 USD-7.35%-3.08%-23.17%+10.27%19.62 M USD
4633
LPCN
Lipocine Inc. - Common Stock
2.35 USD-2.49%-2.89%+3.98%-18.97%19.37 M USD

Notizie